Last updated: July 27, 2025
Introduction
Patent KR20130135836, filed by Samsung Bioepis Co., Ltd., pertains to a biosimilar drug. As part of an ongoing effort to understand South Korea’s pharmaceutical patent landscape, this analysis dissects the scope, claims, and broader landscape surrounding KR20130135836. The patent exemplifies South Korea’s active engagement in biopharmaceutical innovation, particularly biosimilars, and underscores strategic patenting behaviors in a competitive global market.
Patent Overview
KR20130135836 was publicly available for inspection as a patent publication in 2013, titled: "Composition comprising a biosimilar of infliximab and methods of preparation". Its primary focus is on a biosimilar composition closely mimicking infliximab, a monoclonal antibody used to treat autoimmune diseases such as rheumatoid arthritis.
This patent is emblematic of South Korea’s burgeoning biosimilar sector, driven by both domestic opportunities and international competitiveness. Samsung Bioepis, the assignee, has been prominent in biosimilar research and development, aligning with South Korea’s national strategy to develop a robust biopharmaceutical industry.
Scope and Claims Analysis
Core Focus of the Patent
The patent's core claim revolves around the composition of a biosimilar infliximab product, emphasizing its production process, formulation, and characterization. It seeks to establish proprietary rights over specific biosimilar formulations that match the therapeutic profile of reference infliximab.
Claim Structure
The patent comprises multiple claims—primarily independent claims that define the composition, and dependent claims that specify particular features such as glycosylation patterns, formulation stability, and method of manufacturing.
Independent Claims
- Claim 1 automates the composition of a biosimilar infliximab comprising an antibody immunologically similar to infliximab, characterized by specific structural and functional properties.
- Claim 2 stipulates the methods of preparing the composition, focusing on expression in specific cell lines (e.g., CHO cells), purification steps, and formulation parameters.
Dependent Claims
- Define conjugation specifics, glycosylation levels, and stabilization techniques.
- Cover various formulation embodiments, including formulations with stabilizers, preservatives, and buffer systems.
- Include claims on methods of producing the biosimilar, emphasizing cloning, expression, and purification steps that achieve the desired bioequivalence.
Scope of the Claims
The scope spans:
- Biological composition: A biosimilar infliximab with specified structural and functional similarities.
- Manufacturing methods: Techniques to produce the biosimilar with defined quality attributes.
- Formulation specifics: Stabilizers, buffers, and excipients that maintain activity and stability.
While the claims are broad enough to cover general biosimilar formulations, they are specific in areas such as glycosylation patterns and production techniques, indicating an intent to protect both the composition and process.
Patent Landscape for Biosimilar Drugs in South Korea
South Korea as a Biosimilar Hub
South Korea has established a strong domestic platform fostering biosimilar innovations, with major players like Samsung Bioepis and Celltrion. The Korean Intellectual Property Office (KIPO) has seen an uptick in patents related to biosimilar formulations, manufacturing processes, and characterizations.
Key Overlapping Patents and Competitors
KR20130135836 parallels patents filed by companies such as Celltrion (e.g., patents on infliximab biosimilars), with overlapping claims concerning antibody composition, glycosylation, and production methods.
The patent landscape features:
- Broad-based claims covering analytical characterization of biosimilars.
- Process patents focusing on expression systems and purification.
- Formulation patents targeting stability and delivery.
Innovative Chinese and US Biosimilar Patents
South Korean patents, including KR20130135836, are often aligned with international patent families, with equivalents filed in China (CN) and the US (US patents), reflecting strategic global patenting to extend market exclusivity and collaboration rights.
Legal Status and Patent Life
As a 2013 publication, the patent was likely filed around 2011-2012, with a typical patent term of 20 years from filing, suggesting expiry around 2031-2032, barring extensions or legal challenges. The patent’s enforceability and scope are vital for market competition, especially amid the expiration of pioneering biologics.
Implications for Industry and Market
The patent’s claims safeguard specific biosimilar formulations and processes, discouraging competitors from entering the market with similar products without licensing. Ministries and industry stakeholders regard such patents as barriers to generic biosimilar entry, influencing pricing strategies and market dynamics.
South Korea's patent landscape demonstrates a strategic mix of narrow and broad claims to preserve competitive advantage. Patent KR20130135836 reflects the country's emphasis on process innovation—integral for biosimilar manufacturing—complemented by formulation claims.
Conclusion
Patent KR20130135836 exemplifies South Korea’s cutting-edge biosimilar patent strategies, combining composition, process, and formulation claims. It is aligned with the country’s broader initiative to become a leader in affordable biologics, leveraging robust patent protections for innovative biosimilar products.
The patent landscape indicates fierce competition, with companies meticulously carving out claims around specific structural features and production methods. This dynamic shapes South Korea's pharmaceutical ecosystem, influencing global biosimilar market entry strategies and patent litigations.
Key Takeaways
- Scope of KR20130135836 emphasizes composition and manufacturing process of infliximab biosimilars, aiming to protect specific structural and functional features.
- Claims breadth covers both product formulations and methods, providing comprehensive protection and deterring imitators.
- South Korea's biosimilar patent landscape is competitive and strategically sophisticated, with overlapping claims and active patent filings in related jurisdictions.
- Market implications include enhanced exclusivity for patentees, influencing biosimilar pricing and availability.
- Legal evolution suggests the patent’s validity should be monitored for potential challenges or extensions, influencing long-term market dynamics.
FAQs
1. How does KR20130135836 compare to international biosimilar patents?
It aligns with global claims by covering both structure and manufacturing processes, similar to patents filed in the US and Europe, reflecting South Korea's strategy to secure broad rights internationally.
2. What is the significance of the glycosylation claims in this patent?
Glycosylation affects biosimilar efficacy and immunogenicity. Claims pertaining to glycosylation ensure biosimilar similarity in quality and safety, providing an inventive edge.
3. Are there any legal challenges or disputes associated with this patent?
No known litigations or oppositions are publicly documented as of now. However, biosimilar patents often face scrutiny during market entry, especially with patent interferences and validity challenges.
4. How long will KR20130135836 provide exclusive rights?
Typically, South Korean patents last 20 years from the filing date, suggesting potential expiry around 2031-2032, unless extended or litigated.
5. What are the prospects of biosimilar patent innovations in South Korea?
South Korea continues to prioritize biosimilar innovation, emphasizing process and formulation patents that bolster domestic industry and reduce dependence on patent expiry of original biologics.
References
- [1] South Korean Patent Application KR20130135836.
- [2] South Korean Intellectual Property Office (KIPO) patent database.
- [3] Biosimilar patent landscape reports, Pharmaprojects & IAM.
- [4] Samsung Bioepis official disclosures and patent filings.
